DRAFT landscape of COVID-19 candidate vaccines –

20 March 2020

2 candidate vaccines in clinical evaluation

Platform Type of Developer Coronavirus Current stage of Same platform for
candidate target clinical non-Coronavirus
vaccine evaluation/regulatory candidates
status- Coronavirus
candidate
Non- Adenovirus CanSino Biological COVID-19 Phase 1 Ebola
Replicating Type 5 Vector Inc. ChiCTR2000030906
Viral Vector and Beijing Institute
of Biotechnology

RNA LNP- Moderna/NIAID COVID-19 Phase 1 multiple candidates

encapsulated NCT04283461
mRNA

42 candidate vaccines in clinical evaluation

Platform Type of Developer Coronavirus Current stage of Same platform for
candidate target clinical non-Coronavirus
vaccine evaluation/regulatory candidates
status- Coronavirus
candidate
DNA DNA plasmid Inovio COVID-19 Pre-Clinical Lassa, Nipah
vaccine Pharmaceuticals HIV
Electroporation Filovirus
device HPV
Cancer indications
Zika
Hepatitis B
DNA DNA Takis/Applied DNA COVID-19 Pre-Clinical
Sciences/Evvivax

DNA DNA plasmid Zydus Cadila COVID-19 Pre-Clinical

vaccine

Inactivated Formaldehyde- Sinovac COVID-19 Pre-Clinical SARS

inactivated +
alum

Live Deoptimized Codagenix/Serum COVID-19 Pre-Clinical HAV, InfA, ZIKV, FMD,

Attenuated live attanuated Institute of India SIV, RSV, DENV
Virus vaccines

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020
global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be
deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes
reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all)
representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned
purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any
of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss,
damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of
these landscape documents.
 Non- MVA encoded GeoVax/BravoVax COVID-19 Pre-Clinical LASV, EBOV, MARV,
Replicating VLP HIV
Viral Vector

Non- Ad26 (alone or Janssen COVID-19 Pre-Clinical Ebola, HIV, RSV

Replicating with MVA Pharmaceutical
Viral Vector boost) Companies

Non- ChAdOx1 University of Oxford COVID-19 Pre-Clinical influenza, TB,

Replicating Chikungunya, Zika,
Viral Vector MenB, plague

Non- adenovirus- Altimmune COVID-19 Pre-Clinical influenza

Replicating based NasoVAX
Viral Vector expressing
SARS2-CoV
spike protein

Non- Ad5 S Greffex COVID-19 Pre-Clinical MERS

Replicating (GREVAX™
Viral Vector platform)

Non- Oral Vaccine Vaxart COVID-19 Pre-Clinical InfA, CHIKV, LASV,

Replicating platform NORV; EBOV, RVF,
Viral Vector HBV, VEE

Protein Drosophila S2 ExpreS2ion COVID-19 Pre-Clinical

Subunit insect cell
expression
system VLPs

Protein S protein WRAIR/USAMRIID COVID-19 Pre-Clinical

Subunit

Protein S-Trimer Clover COVID-19 Pre-Clinical HIV, REV Influenza

Subunit Biopharmaceuticals
Inc./GSK

Protein Peptide Vaxil Bio COVID-19 Pre-Clinical

Subunit

Protein S protein AJ Vaccines COVID-19 Pre-Clinical

Subunit

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020
global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be
deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes
reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all)
representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned
purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any
of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss,
damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of
these landscape documents.
 Protein Ii-Key peptide Generex/EpiVax COVID-19 Pre-Clinical Influenza, HIV, SARS-
Subunit CoV

Protein S protein EpiVax/Univ. of COVID-19 Pre-Clinical H7N9

Subunit Georgia

Protein S protein Sanofi Pasteur COVID-19 Pre-Clinical Influenza, SARS-CoV

Subunit (baculovirus
production)

Protein Full length S Novavax COVID-19 Pre-Clinical RSV; CCHF, HPV, VZV,
Subunit trimers/ EBOV
nanoparticle +
Matrix M

Protein gp-96 backbone Heat Biologics/Univ. COVID-19 Pre-Clinical NSCLC, HIV, malaria,
Subunit Of Miami Zika

Protein Molecular University of COVID-19 Pre-Clinical Nipah, influenza,

Subunit clamp Queensland/GSK Ebola, Lassa
stabilized Spike
protein

Protein S1 or RBD Baylor College of COVID-19 Pre-Clinical SARS

Subunit protein Medicine

Protein Subunit iBio/CC-Pharming COVID-19 Pre-Clinical

Subunit protein, plant
produced

Protein Subunit VIDO-InterVac, COVID-19 Pre-Clinical

Subunit University of
Saskatchewan

Protein Adjuvanted University of COVID-19 Pre-Clinical

Subunit microsphere Saskatchewan
peptide

Replicating Measles Vector Zydus Cadila COVID-19 Pre-Clinical

Viral Vector

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020
global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be
deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes
reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all)
representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned
purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any
of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss,
damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of
these landscape documents.
 Replicating Measles Vector Institute COVID-19 Pre-Clinical West nile, chik, Ebola,
Viral Vector Pasteur/Themis/Univ. Lassa, Zika
of Pittsburg Center
for Vaccine Research

Replicating Horsepox Tonix COVID-19 Pre-Clinical Smallpox, monkeypox

Viral Vector vector Pharma/Southern
expressing S Research
protein

RNA LNP- Fudan University/ COVID-19 Pre-Clinical

encapsulated Shanghai JiaoTong
mRNA cocktail University/RNACure
encoding VLP Biopharma

RNA LNP- Fudan University/ COVID-19 Pre-Clinical

encapsulated Shanghai JiaoTong
mRNA University/RNACure
encoding RBD Biopharma

RNA mRNA China CDC/Tongji COVID-19 Pre-Clinical

University/Stermina

RNA mRNA Arcturus/Duke-NUS COVID-19 Pre-Clinical multiple candidates

RNA mRNA BioNTech/Fosun COVID-19 Pre-Clinical

Pharma/Pfizer

RNA saRNA Imperial College COVID-19 Pre-Clinical EBOV; LASV, MARV,

London Inf (H7N9), RABV

RNA mRNA Curevac COVID-19 Pre-Clinical RABV, LASV, YFV;

MERS, InfA, ZIKV,
DengV, NIPV
VLP Plant-derived Medicago Inc. COVID-19 Pre-Clinical Flu, Rotavirus,
VLP Norovirus, West Nile
virus, Cancer
Unknown Unknown University of Hong COVID-19 Pre-Clinical
Kong
Unknown Unknown ImmunoPrecise COVID-19 Pre-Clinical

Unknown Unknown MIGAL Galilee COVID-19 Pre-Clinical

Research Institute
Unknown Unknown Doherty Institute COVID-19 Pre-Clinical

Unknown Unknown Tulane University COVID-19 Pre-Clinical

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020
global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be
deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes
reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all)
representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned
purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any
of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss,
damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of
these landscape documents.